AC
ADVM

Ascend Capital’s Adverum Biotechnologies ADVM Stock Holding History

Ascend Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2.09M Buy
+34,581
New +$1.94M 0.11% 133
2015
Q4 		– Sell
-35,940
Closed -$2.96M – 144
2015
Q3 		$2.96M Buy
+35,940
New +$4.59M 0.12% 103
2015
Q2 		– Sell
-2,000
Closed -$811K – 141
2015
Q1 		$811K Buy
+2,000
New +$845K 0.03% 155

Other funds holding ADVM

MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Ascend Capital's ADVM Position: Q3 2018 in Review

Ascend Capital opened a new position in Adverum Biotechnologies (ADVM) in Q3 2018: 34,581 shares worth $2.09M. The stake represents 0.11% of the portfolio and ranks #133 among its holdings. This is a return to the name: Ascend Capital previously reported a position in ADVM as recently as Q3 2015.

Ascend Capital first reported a position in ADVM in Q1 2015 and has held it in 3 quarters since. The position peaked at $2.96M in Q3 2015. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

  • Ascend Capital held 34,581 shares of Adverum Biotechnologies worth $2.09M as of Q3 2018.
  • Adverum Biotechnologies was a new Ascend Capital position in Q3 2018.
  • Adverum Biotechnologies made up 0.11% of Ascend Capital's portfolio in Q3 2018, its #133 holding.
  • Ascend Capital first reported a position in Adverum Biotechnologies in Q1 2015 and has held it in 3 quarters since.
  • Ascend Capital's Adverum Biotechnologies position peaked at $2.96M in Q3 2015.
  • 101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.